SINGAPORE and JAKARTA, INDONESIA – November 30, 2011 – Quintiles today announced an expanded partnership with Jakarta-based Prodia Clinical Laboratory through its sister company Prodia the CRO, to facilitate rapid testing of samples from patients in clinical trials in Indonesia. The partnership will help Quintiles’ biopharmaceutical customers establish the benefits of new medicines in Indonesian patients .
Under the agreement, Prodia will provide Quintiles with exclusive access to its central laboratory services for a two-year period.
“This agreement demonstrates Quintiles’ commitment to improving human health in Indonesia by participating in global clinical research and development,” said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines. “Indonesia has an ethnically diverse population of 240 million. Major health issues in the region include infectious and non-communicable diseases, with mental health problems and tobacco-related illnesses also on the rise.
“As new and improved medicines are developed for these conditions, it’s important that they are studied in populations for whom they are intended, including Indonesian patients.”
Prodia the CRO President, Gunawan Prawiro Suharto said, “As the local market leader in laboratory services, Prodia is delighted to partner with Quintiles to help establish Indonesia as a true centre of excellence for delivery of clinical trials. We look forward to working with Quintiles and its global biopharma customers to develop novel therapies.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 24,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics.
Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. In Asia Pacific alone, Quintiles has 5,000 employees in 15 countries, and was voted 2010 Asia Pacific CRO of the Year by Frost & Sullivan, and Best CRO by Biopharma Asia Pacific 2011. For more information, please visit www.quintiles.com.
About Prodia Clinical Laboratory
Prodia Clinical Laboratory, one of the largest and the best clinical laboratories in Asia for nearly 39 years, provides a wide range of laboratory testing services. Quality is first priority from the time subjects are prepared for specimens collection up to final data analysis. Prodia was the first clinical laboratory in Indonesia to meet with ISO 9001 & ISO 15189 standards, and has recently obtained certification from the National Glycohemoglobin Standardisation Program (NGSP) Level 1 for HbA1c standardisation.
It is currently in the process of obtaining CAP (College of American Pathologists) accreditation which is expected to be completed early 2012. It has received awards as National Top Brand for the last 3 consecutive years, and owns a network of 110 branches nationwide to cover patient sampling at any needed site in the country. It has been working in the clinical trial area for nearly 15 years, and later established a sister CRO company. To learn more about Prodia Labs and Prodia the CRO, visit their websites at www.prodia.co.id and www.prodiathecro.com.